Join Our Community
Get the latest cancer stories, helpful resources, and personalized advice directly to your inbox.
Each year, The Patient Story attends a handful of cancer conferences to meet with experts on the frontlines of cancer care and report on developments that matter to patients. We’ve reported on ASH, SABCS, and ASCO. The American Society for Clinical Oncology (ASCO), established in 1964, plays a pivotal role in the global fight against cancer. It was held from May 31 to June 4, 2024. This page provides updates from our attendance.
The American Society for Clinical Oncology (ASCO) and its annual meeting unites over 40,000 professionals from more than 100 countries across various oncology subspecialties and disciplines around the world, all committed to advancing cancer care. This premier organization is at the forefront of fostering innovative research, disseminating critical educational resources, and advocating for high-quality patient care. And we were there.
Docetaxel causes less peripheral neuropathy compared to paclitaxel for Black patients with early-stage breast cancer, potentially making it the preferred treatment.
Durvalumab after chemoradiotherapy significantly improves survival for people with limited-stage small cell lung cancer - receiving a standing ovation.
Osimertinib after chemoradiotherapy extends progression-free survival for stage III NSCLC patients with EGFR mutations.
Combining ipilimumab and nivolumab before surgery, followed by selective adjuvant therapy, improves outcomes for stage III melanoma patients.
A combination of belantamab mafodotin, pomalidomide, and dexamethasone shows promise in treating relapsed or refractory multiple myeloma.
Many breast cancer survivors successfully conceive and give birth post-treatment.
Some advanced ovarian cancer patients may avoid lymph node removal during surgery safely.
An AI-based patient navigation tool may help reduce barriers to colorectal cancer screening in underserved communities.
A new treatment combination cures classical Hodgkin lymphoma more effectively and with fewer side effects than intensive chemotherapy.
Targeted therapy drug asciminib is a safe and effective treatment for chronic phase chronic myeloid leukemia.
Lorlatinib outperforms crizotinib in stopping progression of ALK-positive non-small cell lung cancer.
Trastuzumab deruxtecan slows cancer growth in HR+, HER2-low or HER2-ultralow metastatic breast cancer.
Get the latest cancer stories, helpful resources, and personalized advice directly to your inbox.
Copyright 2024 © The Patient Story
For cancer patients and caregivers.
Quick Links
Additional Links